Literature DB >> 9833747

Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression.

H Hendel1, N Hénon, H Lebuanec, A Lachgar, H Poncelet, S Caillat-Zucman, C A Winkler, M W Smith, L Kenefic, S O'Brien, W Lu, J M Andrieu, D Zagury, F Schächter, J Rappaport, J F Zagury.   

Abstract

The Genetics of Resistance to Infection by HIV-1 (GRIV) cohort represents 200 nonprogressor/slow-progressor (Slowprog) and 90 fast-progressor (Fastprog) HIV-1-infected patients. Using this unique assembly, we performed genetic studies on three recently discovered polymorphisms of CCR5, CCR2, and SDF1, which have been shown to slow the rate of disease progression. The increased prevalence of mutant alleles among Slowprogs from the GRIV cohort was significant for CCR5 (p < .0001) but not for CCR2 (p = .09) or SDF1 (p = . 12), emphasizing the predominant role of CCR5 as the major HIV-1 coreceptor. However, the prevalence of the CCR2 mutant allele (64I) was significantly increased among Slowprogs homozygous for wild-type CCR5 compared with Fastprogs (p = .04). The prevalence of double mutants SDF1-3'A/3'A genotypes was also increased among Slowprogs homozygous for wild-type CCR5 compared with Fastprogs (p = .05). The effects of the CCR2 and SDF1 mutations are overshadowed by the protective effects of the CCR5 deletion. Predictive biologic markers such as CD4 cell counts or viral load in the Slowprog population did not show significant differences between Slowprog groups with wild-type or mutant alleles for the three genes. Thus, our data suggest that the effects of these genes are exerted earlier in infection and no longer evident in the Slowprog of the GRIV cohort whose average duration of HIV infection is 12 years. We conclude that these genes, whose products serve as viral coreceptors or their ligands, may play a role early in infection and delay the onset of disease. However, among Slowprogs, whose duration of infection is >8 years, they are no longer influential for maintenance of their longterm nonprogression status. Other genetic determinants may be responsible for late protective effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9833747     DOI: 10.1097/00042560-199812010-00009

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  22 in total

1.  Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children.

Authors:  Carina A Rodriguez; Sarah Koch; Maureen Goodenow; John W Sleasman
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

2.  Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression.

Authors:  Jianming Tang; Brent Shelton; Nina J Makhatadze; Yuting Zhang; Margaret Schaen; Leslie G Louie; James J Goedert; Eric C Seaberg; Joseph B Margolick; John Mellors; Richard A Kaslow
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  CCR2-64I allele is associated with the progression of AIDS in a Han Chinese population.

Authors:  Lidan Xu; Yuandong Qiao; Xuelong Zhang; Haiming Sun; Jingwei Wang; Donglin Sun; Yan Jin; Yang Yu; Feng Chen; Jing Bai; Hong Ling; Kaili Wang; Songbin Fu
Journal:  Mol Biol Rep       Date:  2009-08-08       Impact factor: 2.316

4.  Maternal SDF1 3'A polymorphism is associated with increased perinatal human immunodeficiency virus type 1 transmission.

Authors:  G C John; C Rousseau; T Dong; S Rowland-Jones; R Nduati; D Mbori-Ngacha; T Rostron; J K Kreiss; B A Richardson; J Overbaugh
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression.

Authors:  Gabriela Bleiber; Margaret May; Raquel Martinez; Pascal Meylan; Jürg Ott; Jacques S Beckmann; Amalio Telenti
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  CCR2, CCR5, and CXCL12 variation and HIV/AIDS in Papua New Guinea.

Authors:  Noemi B Hall; Shannon E Bruse; Bangan John; Rajeev K Mehlotra; Melinda J Blood Zikursh; Catherine M Stein; Peter M Siba; Peter A Zimmerman
Journal:  Infect Genet Evol       Date:  2015-09-28       Impact factor: 3.342

7.  Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study.

Authors:  S N Maley; S M Schwartz; L G Johnson; M Malkki; Q Du; J R Daling; S S Li; L P Zhao; E W Petersdorf; M M Madeleine
Journal:  Int J Immunogenet       Date:  2009-09-24       Impact factor: 1.466

8.  Polymorphisms of RANTES and IL-4 genes in cerebral infarction.

Authors:  Jae-Young Um; Hyung-Min Kim
Journal:  J Mol Neurosci       Date:  2008-08-12       Impact factor: 3.444

9.  Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1.

Authors:  Jianming Tang; Shenghui Tang; Elena Lobashevsky; Angela D Myracle; Ulgen Fideli; Grace Aldrovandi; Susan Allen; Rosemary Musonda; Richard A Kaslow
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Associations of the IL2Ralpha, IL4Ralpha, IL10Ralpha, and IFN (gamma) R1 cytokine receptor genes with AIDS progression in a French AIDS cohort.

Authors:  Hervé Do; Alexandre Vasilescu; Gora Diop; Thomas Hirtzig; Cédric Coulonges; Taoufik Labib; Simon C Heath; Jean-Louis Spadoni; Amu Therwath; Mark Lathrop; Fumihiko Matsuda; Jean-François Zagury
Journal:  Immunogenetics       Date:  2006-02-21       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.